CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, today announced that it has expanded its sales leadership team in the United States with the addition of Chad Zaring as Vice President of National Accounts & Strategic Alliances. Mr. Zaring is a seasoned capital equipment sales executive with over 10 years of success in deploying high impact sales strategies and will be responsible for business development in integrated delivery networks, large hospital and ambulatory surgery center networks, as well as government and academic medical centers. He will report directly to Christopher Sells, Vice President, US Capital Sales.
Prior to joining Mazor, Mr. Zaring held senior sales positions at Intuitive Surgical, Inc., including Vice President Key Accounts, Regional Vice President and Area Sales Director. Prior to joining Intuitive Surgical, he was Division Manager-Northeast Division at Ethicon Endo-Surgery.
“Chad has achieved success throughout his career by combining industry expertise, best practices and innovative sales strategies to cultivate relationships,” commented Christopher Prentice, US CEO of Mazor Robotics. “His extensive experience with robotic system sales and strategic relationships with hospital associations, Group Purchasing Organizations (GPO) and Independent Hospital Networks (IHN) will enable us to drive greater awareness of the Renaissance system within these large healthcare networks and streamline the purchasing decisions.”
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding expectations for the greater awareness of the Renaissance system within large healthcare organizations and the streamlining of purchasing decisions, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.